Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $28.7 million.

  • Cytek Biosciences' Current Deferred Revenue rose 1330.18% to $28.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.7 million, marking a year-over-year increase of 1330.18%. This contributed to the annual value of $25.5 million for FY2024, which is 1232.43% up from last year.
  • According to the latest figures from Q3 2025, Cytek Biosciences' Current Deferred Revenue is $28.7 million, which was up 1330.18% from $28.1 million recorded in Q2 2025.
  • In the past 5 years, Cytek Biosciences' Current Deferred Revenue ranged from a high of $29.6 million in Q2 2023 and a low of $10.9 million during Q2 2021
  • For the 5-year period, Cytek Biosciences' Current Deferred Revenue averaged around $21.9 million, with its median value being $23.3 million (2022).
  • Per our database at Business Quant, Cytek Biosciences' Current Deferred Revenue skyrocketed by 9097.95% in 2021 and then crashed by 4836.99% in 2022.
  • Cytek Biosciences' Current Deferred Revenue (Quarter) stood at $25.2 million in 2021, then crashed by 48.37% to $13.0 million in 2022, then surged by 74.77% to $22.7 million in 2023, then grew by 12.32% to $25.5 million in 2024, then increased by 12.74% to $28.7 million in 2025.
  • Its last three reported values are $28.7 million in Q3 2025, $28.1 million for Q2 2025, and $27.7 million during Q1 2025.